•
Sep 6, 2024
Sep 5, 2024
Aug 14, 2024
Aug 13, 2024
Aug 8, 2024
Aug 29, 2024
Aug 26, 2024
Sep 4, 2024
Aug 28, 2024
Aug 9, 2024
VERU INC. [VERU] has reported fiscal Q2 loss of $38.80 million.
On a per-share basis, the WI based company said its diluted earnings are $0.48.
The Pharmaceutical Preparations firm posted revenue of $6.60 million in this period.
Also Read: Veru Reports Fiscal 2023 Second Quarter Financial ResultsVeru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin ...Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia AssetVeru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales ...Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. ...